Perumal, Jai
Balabanov, Roumen
Su, Ray
Chang, Roger
Balcer, Laura
Galetta, Steven
Campagnolo, Denise I.
Avila, Robin
Lee, Lily
Rutledge, Danette
Fox, Robert J.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
https://doi.org/10.1007/s12325-021-01722-w
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study
https://doi.org/10.1007/s40263-022-00950-0
Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing–Remitting Multiple Sclerosis: STRIVE Data Analysis
https://doi.org/10.1007/s40120-023-00461-0
Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study
https://doi.org/10.1007/s40263-022-00982-6
Funding for this research was provided by:
Biogen
Article History
Received: 26 January 2021
Accepted: 22 March 2021
First Online: 20 May 2021
Change Date: 22 June 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12325-021-01815-6